These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 22710573)

  • 21. Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells.
    Wittmann P; Grubinger M; Gröger C; Huber H; Sieghart W; Peck-Radosavljevic M; Mikulits W
    BMC Cancer; 2015 Nov; 15():909. PubMed ID: 26573807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling.
    Torbenson M; Marinopoulos S; Dang DT; Choti M; Ashfaq R; Maitra A; Boitnott J; Wilentz RE
    Hum Pathol; 2002 Sep; 33(9):871-6. PubMed ID: 12378510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
    Fransvea E; Angelotti U; Antonaci S; Giannelli G
    Hepatology; 2008 May; 47(5):1557-66. PubMed ID: 18318443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
    Ji GZ; Wang XH; Miao L; Liu Z; Zhang P; Zhang FM; Yang JB
    World J Gastroenterol; 2006 Jan; 12(4):644-8. PubMed ID: 16489684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.
    Tang Y; Kitisin K; Jogunoori W; Li C; Deng CX; Mueller SC; Ressom HW; Rashid A; He AR; Mendelson JS; Jessup JM; Shetty K; Zasloff M; Mishra B; Reddy EP; Johnson L; Mishra L
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2445-50. PubMed ID: 18263735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rationale for targeting TGF-β in chronic liver diseases.
    Giannelli G; Mikulits W; Dooley S; Fabregat I; Moustakas A; ten Dijke P; Portincasa P; Winter P; Janssen R; Leporatti S; Herrera B; Sanchez A
    Eur J Clin Invest; 2016 Apr; 46(4):349-61. PubMed ID: 26823073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis.
    Ding W; Mouzaki M; You H; Laird JC; Mato J; Lu SC; Rountree CB
    Hepatology; 2009 Apr; 49(4):1277-86. PubMed ID: 19115422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
    Jang JW; Song Y; Kim SH; Kim JS; Kim KM; Choi EK; Kim J; Seo HR
    Cancer Lett; 2017 Mar; 389():1-10. PubMed ID: 28034805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer stem cells and their niche in the progression of squamous cell carcinoma.
    Oshimori N
    Cancer Sci; 2020 Nov; 111(11):3985-3992. PubMed ID: 32888236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGF-β signaling in onset and progression of hepatocellular carcinoma.
    Meindl-Beinker NM; Matsuzaki K; Dooley S
    Dig Dis; 2012; 30(5):514-23. PubMed ID: 23108308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of cancer stem cell biology in hepatocellular carcinoma.
    Ji J; Wang XW
    Semin Oncol; 2012 Aug; 39(4):461-72. PubMed ID: 22846863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
    Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
    Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hierarchical potential differentiation of liver cancer stem cells.
    Zhang W; Mu D; Feng K
    Adv Clin Exp Med; 2017 Oct; 26(7):1137-1141. PubMed ID: 29211363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma.
    Yamashita T; Honda M; Nakamoto Y; Baba M; Nio K; Hara Y; Zeng SS; Hayashi T; Kondo M; Takatori H; Yamashita T; Mizukoshi E; Ikeda H; Zen Y; Takamura H; Wang XW; Kaneko S
    Hepatology; 2013 Apr; 57(4):1484-97. PubMed ID: 23174907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer.
    Rojas A; Zhang P; Wang Y; Foo WC; Muñoz NM; Xiao L; Wang J; Gores GJ; Hung MC; Blechacz B
    Neoplasia; 2016 Jun; 18(6):371-86. PubMed ID: 27292026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.
    Lin L; Amin R; Gallicano GI; Glasgow E; Jogunoori W; Jessup JM; Zasloff M; Marshall JL; Shetty K; Johnson L; Mishra L; He AR
    Oncogene; 2009 Feb; 28(7):961-72. PubMed ID: 19137011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
    Liu M; Bamodu OA; Kuo KT; Lee WH; Lin YK; Wu ATH; M H; Tzeng YM; Yeh CT; Tsai JT
    Am J Chin Med; 2018; 46(4):891-910. PubMed ID: 29792038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.
    Coulouarn C; Cavard C; Rubbia-Brandt L; Audebourg A; Dumont F; Jacques S; Just PA; Clément B; Gilgenkrantz H; Perret C; Terris B
    Carcinogenesis; 2012 Sep; 33(9):1791-6. PubMed ID: 22696594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma.
    Huang W; Yu D; Wang M; Han Y; Lin J; Wei D; Cai J; Li B; Chen P; Zhang X
    Cell Prolif; 2020 Jul; 53(7):e12836. PubMed ID: 32537856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
    Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
    BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.